Cytokinetics Inc. (CYTK)
Cytokinetics' Myqorzo gains FDA approval, driving stock to a 52-week high amidst analyst optimism, though market sentiment and competition remain factors.
About Cytokinetics Inc.
Cytokinetics Inc. is a biopharmaceutical company focused on the development of muscle activators.
Cytokinetics Inc. uses the ticker $CYTK for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Cytokinetics Inc. (CYTK) sentiment is up 150% from the previous week.
- Cytokinetics Inc. (CYTK) creators is up 17.24% from the previous week.
- Cytokinetics Inc. (CYTK) mentions is up 17.54% from the previous week.
- Cytokinetics Inc. (CYTK) posts created is up 462.5% from the previous week.
Price: $66.30
Price 24-Hour Time-Series Raw Data
The stock price has surged to a 52-week high, driven by the FDA approval of Myqorzo and positive analyst sentiment, despite some valuation concerns and general market negativity.
24-Hour: 1.18% 7-Day: 4.58% 30-Day: 5.88%
1-Year High: $68.20 on 2025-11-26
1-Year Low: $29.80 on 2025-05-15
AltRank: [-----]
AltRank 24-Hour Time-Series Raw Data
Cytokinetics Inc. (CYTK) is currently AltRank #1,145 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [-----] [----]
[--] Month: [-----] +613
[--] Months: [-----] +336
[--] Year: [-----] +720
1-Year High: [-----] on 2025-06-29
1-Year Low: [--] on 2025-09-02
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] [---]
[--] Months: [--] [---]
[--] Year: [--] [---]
1-Year High: [--] on 2025-04-24
1-Year Low: [--] on 2025-08-01
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [------] -39%
[--] Month: [-------] -76%
[--] Months: [---------] +74%
[--] Year: [---------] +8.70%
1-Year High: [-------] on 2025-09-02
1-Year Low: [---] on 2026-02-08
Engagements by network (24h): TikTok: [--] News: [-----] Reddit: [--] X: [-----] YouTube: [--]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [---]
[--] Week: [---] +18%
[--] Month: [-----] +5%
[--] Months: [-----] +48%
[--] Year: [-----] +3.40%
1-Year High: [---] on 2025-09-03
1-Year Low: [--] on 2025-06-13
Mentions by network (24h): TikTok: [--] News: [--] Reddit: [--] X: [--] YouTube: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Cytokinetics Inc. (CYTK) in the last [--] hours which is down 9.90% from [--] in the previous [--] hours
Daily Average: [--]
[--] Week: [---] +17%
[--] Month: [---] +11%
[--] Months: [-----] +1.40%
[--] Year: [-----] +75%
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2025-05-24
The most influential creators that mention Cytokinetics Inc. in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Andre_AGTC | [--] | [-----] | [--] | [---] |
| @Quantumup1 | [--] | [-----] | [--] | [---] |
| @Pharmdca | [--] | [-------] | [--] | [---] |
| @_le_Lounge | [--] | [-----] | [--] | [--] |
| @WolfOfPathogens | [--] | [--] | [--] | [--] |
| @mda | [--] | [------] | [--] | [--] |
| @seedytx19 | [--] | [-----] | [--] | [--] |
| @PersimmonTI | [--] | [------] | [--] | [--] |
| @SteveDJacobs | [--] | [------] | [--] | [--] |
Sentiment: 71%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 71%
Daily Average: 73%
[--] Week: 100% +60%
[--] Month: 68% +8%
[--] Months: 68% -9%
[--] Year: 68% -6%
1-Year High: 100% on 2025-04-22
1-Year Low: 26% on 2025-12-07
Most Supportive Themes:
- FDA Approval of Myqorzo: (70%) Cytokinetics' aficamten (Myqorzo) has received FDA approval for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking a significant milestone for the company.
- Myqorzo's Differentiated Profile: (20%) Market analysis suggests Myqorzo's label and REMS program are differentiated from competitors like Camzyos, potentially offering advantages in administration and monitoring.
- Positive Analyst Sentiment and Price Targets: (10%) Analysts have reiterated outperform ratings and increased price targets for CYTK, citing the FDA approval and Myqorzo's strong market potential.
Most Critical Themes:
- General Market Sentiment: (50%) Despite positive company-specific developments, general negative market sentiment is currently influencing commentary about Cytokinetics Inc. (CYTK).
- Competition from Camzyos: (30%) While Myqorzo shows promise, it faces competition from an entrenched competitor, Camzyos, and its market adoption will be closely watched.
- Valuation Concerns: (20%) Some users express difficulty in justifying the current valuation for CYTK, despite the positive news, indicating potential overvaluation concerns.
Social Dominance: 0.00539%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00539%
Daily Average: 0.018%
[--] Week: 0.0051% -0.0036%
[--] Month: 0.0065% -0.0058%
[--] Months: 0.0065% -0.0058%
[--] Year: 0.0065% -0.016%
1-Year High: 0.079% on 2025-09-03
1-Year Low: 0.0059% on 2025-10-24
Market Dominance: 0.00918%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00918%
Daily Average: 0%
1-Year High: 0.021% on 2025-03-31
1-Year Low: 0.00491% on 2025-05-15
Market Cap: $8,101,274,196
Market Cap 24-Hour Time-Series Raw Data
Current Value: $8,101,274,196
Daily Average: $5,815,567,535
[--] Week: $8,101,274,196 +4.60%
[--] Month: $8,101,274,196 +5.90%
[--] Months: $8,101,274,196 +81%
[--] Year: $8,101,274,196 +49%
1-Year High: $8,332,354,911 on 2025-11-26
1-Year Low: $3,563,710,423 on 2025-05-15
Top Cytokinetics Inc. News
Top news links shared on social in the last [--] hours
Showing a maximum of [--] news posts without a LunarCrush subscription.
"Top 2% Biotech Hits Slam Dunk On Bid To Edge Out Bristol Cytokinetics Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb just behind Cytokinetics"
News Link @dbielecki21 2024-09-19T13:44Z 208.1M followers, [----] engagements
Top Cytokinetics Inc. Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"#Deeptrack Feb 13'26 Massive $XBI put 22% of portfolio Vary bearish moveđź‘€ Changed position of interest $XBI put New #1 $IMVT +19% #2 $AXSM +28% #7 $CYTK -22% #6 $VRDN -53% #19"
X Link @Andre_AGTC 2026-02-14T18:26Z [----] followers, [----] engagements
"Piper Sandler reiterated Best Idea $EWTX at Overweight-$51 and said Addressing [--] Investor Questions on EWTX's Cardio Franchise $CYTK BMY $CAPR SLDB DYN SRPT PTCT Piper Sandler added EWTX has been one of our best ideas for [----] so we continue to view this as a top-pick into EDG-7500's 12-week Part D Ph2 CIRRUS-HCM 2Q26 topline. Hence we compiled this Deep Dive tackling [--] frequently-asked investor questions that ultimately increases our conviction call for a positive readout highlighting EDG-7500's differentiated value proposition and lucrative HCM opportunity. Moreover we dig into EDG-15400"
X Link @Quantumup1 2026-02-09T14:17Z [----] followers, [----] engagements
"LT position into [----] Part [--] # [--] Portfolio Pick Buyouts $RNA $NARI $BPMC $MYOV $IMGN $KRTX $HZNP $PRVB $ISEE $BLU $CTIC $FSTX $ICVX $LVGO $STML $JUNO $CMRX $RLYP $ITCI $KVUE Tech positions in order- $AMZN $TSLA $SOFI $COIN $GOOG $NVDA $AMD $RBRK $META $NFLX $UBER $MSFT $AVGO $ZS $MELI $IREN $NBIS Top Biotech positions: $VKTX $CYTK $BBIO $TMDX $MDGL $HROW $SLNO $IMNM $GPCR $OCUL $CRVS https://twitter.com/i/web/status/2002067407834374356 https://twitter.com/i/web/status/2002067407834374356"
X Link @Pharmdca 2025-12-19T17:24Z 108.6K followers, 56.5K engagements
"Truist reiterated $EWTX Buy-$46 and said We See Risk/Reward of 30-40% Up/20-30% Down into 4Q data $CYTK $BMY Truist added As we head into Ph2 HCM readout in 4Q we reiterate our Buy rating. As a reminder EWTX reported data from Ph2 B/C cohorts in April. While data showed favorable efficacy & LVEF excursion rates with potential to differentiate vs CMIs incidence of atrial fibrillation became a primary concern for investors. We see risk/reward of 30-40% up/20-30% down into 4Q data & note 1) Part D patient screening is key (details below); 2) KOL checks do not highlight AF as a concern; 3) In our"
X Link @Quantumup1 2025-11-03T14:39Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing